Navigation Links
ChromaDex Licenses Additional Technology for pTeroPure® From the University of Mississippi
Date:6/9/2011

IRVINE, Calif. and OXFORD, Miss., June 9, 2011 /PRNewswire/ -- ChromaDex Corp. (OTCBB: CDXC) and the University of Mississippi today announced the university has granted the natural products company the exclusive worldwide patent rights to a potential new therapeutic use for pterostilbene (tero-STILL-bean) as an anxiolytic or anti-anxiety agent. ChromaDex' pTeroPure® is an ultra-pure formulation of pterostilbene, a compound found in blueberries and demonstrated to have multiple health benefits.

ChromaDex continues its strategy of expanding its intellectual property supporting pterostilbene as the company builds its pTeroPure product portfolio and seeks partnerships to enter new markets. ChromaDex previously licensed two patents from the University of Mississippi that focus on the ability of pterostilbene to reduce blood lipoprotein levels and pterostilbene's effect on oxidative stress and cognition. ChromaDex also holds rights to patents related to manufacturing claims.

"Adding the anxiolytic indication to our existing patent portfolio around pTeroPure allows us to capitalize on new product opportunities that we can pursue independently or with partners looking to differentiate their own products," said ChromaDex President William Spengler. "ChromaDex will continue to seek partners such as the University of Mississippi so as to capture advancements in natural product research that will allow us to provide the marketplace with innovative proprietary ingredients."

Research conducted by the University of Mississippi School of Pharmacy shows pterostilbene may have anxiolytic activities. The researchers determined pterostilbene activates the ERK signaling pathway in the hippocampus, an area of the brain speculated to play a role in anxiety. The effect of pterostilbene was investigated in a classic animal model of anxiety and found to be comparable in activity to the anti-anxiety drug diazepam used as the control drug in the model.

"We value our relationship with ChromaDex as a partner that has demonstrated a strong ability to commercialize products borne from our research to benefit people's health and wellbeing," said Walter Chambliss, Director Technology Management at the University of Mississippi.

The first human clinical research study on pTeroPure is being conducted at the University of Mississippi Medical Center to evaluate the compound in patients with lipid (cholesterol) disorders. Primary outcome measures include standard lipid laboratory markers. Secondary endpoints include blood pressure, markers of oxidative stress and safety.

For more information about pTeroPure, visit www.pteropure.com or call 949-600-9694.

About ChromaDex

ChromaDex is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries.  The company has an impressive pipeline of new ingredients, including its pTeroPure® pterostilbene for which it has worldwide, exclusive patent rights.  

About the University of Mississippi

The University of Mississippi School of Pharmacy has earned international recognition for accomplishments in education; basic, translational and clinical research; and professional and community service. The school's faculty members are heavily involved in teaching, research and patient care in a variety of settings, and it is home to the National Center for Natural Products Research, the nation's only university research center devoted to improving human health and agricultural productivity through the discovery, development and commercialization of pharmaceuticals and agrochemicals derived from plants, marine organisms and other natural products.

ChromaDex Forward-Looking Statements

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

ChromaDex Investor Inquiries:
Liviakis Financial Communications, Inc.
John M. Liviakis, President
415-389-4670
John@Liviakis.com

pTeroPure Contact:
Jeremy Bartos
Product Development Manager
949-600-9694
jeremyb@pteropure.com

ChromaDex Media Inquiries:
Carolyn Hawley
Canale Communications
619-849-5375
carolyn@canalecomm.com

University of Mississippi Contact:
Mitchel Diggs
Associate Director
Media and Public Relations
662-915-5639
mdiggs@olemiss.edu


'/>"/>
SOURCE ChromaDex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Life Extension® Launches New Product Containing ChromaDexs pTeroPure® Pterostilbene
2. Nutraceutical International Corporation Launches Product Featuring ChromaDexs pTeroPure™ Pterostilbene
3. ChromaDex and Bruker Optics Sign Agreement to Expedite Dietary Supplement Testing for Compliance With FDA Good Manufacturing Practice Requirements
4. ChromaDex Partners With Kappa Bioscience to Provide Quality Control Methods, Tools and Services for Vitamin K2
5. Centella Therapeutics Licenses Novel New Drug Designed to Enhance the Effectiveness of Cancer Treatment
6. Biomerix Awarded Two Device Licenses by Health Canada
7. China Sky One Medical Obtains Production Licenses for Thirteen New Medical Products
8. Oxford BioTherapeutics Licenses BioWas POTELLIGENT® Technology for the Research and Development of its Therapeutic Antibodies in Cancer
9. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
10. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
11. Novavax Licenses Recombinant VLP Influenza Vaccine to LG Life Sciences for South Korea and Other Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... March 22, 2017 AMRI , a ... been working with the life sciences industry to improve ... 25 years, has been recognized for its excellence as ... as part of the Life Science Leader,s 2017 ... expertise, quality and reliability. "Competing with ...
(Date:3/22/2017)... STOCKHOLM , March 22, 2017 ... biopharmaceutical company developing novel anticancer therapies targeting the ... with Memorial Sloan Kettering Cancer Center to study ... p53 by APR-246. The goal of ... efficacy of APR-246 in combination with multiple other ...
(Date:3/22/2017)... Research and Markets has announced the addition of the "Global ... ... market to grow at a CAGR of 14.58% during the period ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... March 22, 2017 , ... Last year, 43 million ... US Department of Agriculture report. While excess dairy can be caused by several ... Lactose sensitivity is the inability to properly digest lactose, a sugar found in milk ...
(Date:3/22/2017)... Park Ridge, NJ (PRWEB) , ... March 22, ... ... financial planning firm that serves communities throughout north Jersey and the New York ... Bergen County to provide regional support for homeless families. , At present, more ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Vanderbeck Agency, a Long ... Nassau County region, is embarking on a combined charity effort with the Great Neck ... the last 25 years, the Great Neck Breast Cancer Coalition has worked to support ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... services to regional families and business owners, is joining the Teen Recovery Solutions ... in the area. , A growing number of Oklahoma teens and adolescents face ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Zabbia Insurance Agency, a ... and business owners in the greater Nassau County area, is embarking on a ... Every 3 minutes, someone in America is diagnosed with blood cancer. Every 9 ...
Breaking Medicine News(10 mins):